Teva Acquires Actavis Generics Joining forces to build our new future Share on Facebook Share on LinkedIn Share on Twitter ✉ At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future.The acquisition delivers on these objectives, while enabling us to take a leading position in our transforming industry.This strategic acquisition brings together two leading generics businesses with complementary strengths, brands and cultures, providing patients with more affordable access to quality medicines, and creating significant financial benefits for Teva stockholders.Our newly combined company offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale. Read more in the press release Actavis Regional Contacts Teva welcomes our Actavis Generics local markets. We want to ensure that each region continues to receive the support it needs during this time of transition. Please see the following table for Actavis business regional contact information.
At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future.The acquisition delivers on these objectives, while enabling us to take a leading position in our transforming industry.This strategic acquisition brings together two leading generics businesses with complementary strengths, brands and cultures, providing patients with more affordable access to quality medicines, and creating significant financial benefits for Teva stockholders.Our newly combined company offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale. Read more in the press release Actavis Regional Contacts Teva welcomes our Actavis Generics local markets. We want to ensure that each region continues to receive the support it needs during this time of transition. Please see the following table for Actavis business regional contact information.
CANADA Medical Affairs Tel: 1-855-892-8766 Side Effects and Lack-of-Efficacy Complaints: 1-800-268-4127 ext. 1255005 Product Inquiries: 1-800-268-4129, 1-416-291-9595 Customer care, product availability, returns and product quality complaints: costumer.service@tevacanada.com Teva Canada Ltd. site Teva Canada Innovation (Specialty Branded products)All Inquiries: 1-866-329-0095 Medical Affairs and Drug Information Teva Canada Innovation site Actavis site
FINLAND General inquiries and Medical Affairs Tel: +358 20 180 5900 Drug Safety Actavis site Teva site
NORWAY General inquiries and Medical AffairsTel: +47 66775590 (Press 1 for medical questions) Actavis site Teva site
SWEDEN General inquiries and Medical AffairsTel: +46 42121100 (Press 1 for medical questions) Actavis site Teva site
UKRAINE General inquiriesTel: +380 44 594 70 80 Medical Affairs Drug Safety Tel: +38 044 594 70 80 Quality Complaints Tel: +38 044 594 70 80 Actavis site Teva site
Share on Facebook Share on LinkedIn Share on Twitter ✉ Media relationsIris Beck Codner, - +972-3-9267208 (Israel) orDenise Bradley, 215-591-8974 (United States)Investor relationsKevin C. Mannix, 215-591-8912 (United States) orRan Meir, 215-591-3033 (United States) orTomer Amitai, 972 (3) 926-7656 (Israel)
Media relationsIris Beck Codner, - +972-3-9267208 (Israel) orDenise Bradley, 215-591-8974 (United States)Investor relationsKevin C. Mannix, 215-591-8912 (United States) orRan Meir, 215-591-3033 (United States) orTomer Amitai, 972 (3) 926-7656 (Israel)